Search company, investor...

Predict your next investment

Angel Investor (Individual)

Investments

5

Portfolio Exits

2

About David Cleevely

David Cleevely is the founder of Analysys, and Managing Director of Analysys Group. His focus areas include authority on the digital economy, regularly commenting on industry trends and prospects at international conferences and in the media. He has also worked with governments at a national and supra-national level to create the policy frameworks which encourage innovation and growth. He advised the UK government on its ecommerce@its.best.uk report, and, also contributed to government thinking on convergence and the Internet. David backed the development of the Cambridge Network, which promotes the high-tech activities of the Cambridge region, primarily via an Analysys-designed Web site. He is also Chairman of Abcam (the world's first totally Internet-based antibody company) and VBN, an Analysys spin-off which provides hosted Web sites for organisations wishing to develop online communities.

Headquarters Location

111 Huntington Avenue Tenth Floor

Boston, Massachusetts, 02199,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest David Cleevely News

Sanome Raises £2M in First Funding

Sep 28, 2021

Sanome , a London, UK-based health startup, raised £2m in first round of funding. The round was led by Heal Capital, with participation from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind and a number of high-profile angels including David Cleevely and Pam Garside. The investment will be used to expand the team across London, Amsterdam, and Cambridge; deliver on key strategic and commercial partnerships to develop and validate the first set of IVD candidates. Founded by experienced entrepreneurs Benedikt von Thüngen (CEO) and Dr Marc van der Schee (Chief Medical Officer), Sanome has developed a diagnostics innovation engine that combines biomarkers to develop medical grade, at home diagnostic products (IVDs) effectively. The company’s home test are clinically validated to improve patient outcomes and reduce healthcare costs. FinSMEs 28/09/2021

David Cleevely Investments

5 Investments

David Cleevely has made 5 investments. Their latest investment was in Sanome as part of their Seed VC on September 9, 2021.

CBI Logo

David Cleevely Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/28/2021

Seed VC

Sanome

$2.69M

Yes

6

7/14/2015

Seed

Subscribe to see more

$99M

Subscribe to see more

10

3/25/2013

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/15/2011

Series B - II

Subscribe to see more

$99M

Subscribe to see more

0

5/14/2010

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/28/2021

7/14/2015

3/25/2013

9/15/2011

5/14/2010

Round

Seed VC

Seed

Series A

Series B - II

Series D

Company

Sanome

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.69M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

10

10

0

10

David Cleevely Portfolio Exits

2 Portfolio Exits

David Cleevely has 2 portfolio exits. Their latest portfolio exit was Privitar on June 14, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/14/2023

Acquired

$99M

5

3/24/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/14/2023

3/24/2014

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

5

10

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.